Salman Razvi1,2, Vicky Ryan3, Lorna Ingoe2,4, Simon H Pearce1,4, Scott Wilkes5. 1. Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom. 2. Department of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, United Kingdom. 3. Institute of Health and Society, Newcastle University, Newcastle, United Kingdom. 4. Department of Endocrinology, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom. 5. School of Medicine, University of Sunderland, Sunderland, United Kingdom.
Abstract
INTRODUCTION: Serum thyroid-stimulating hormone (TSH) increases with age but target TSH is similar in younger and older hypothyroid patients on treatment. It is unknown if quality of life (QoL), hypothyroid symptoms and cardiovascular risk factors change in older hypothyroid patients treated to an age-appropriate reference range. OBJECTIVE: To assess if a higher target serum TSH of 4.01-8.0 mU/L is feasible in, and acceptable to, older treated hypothyroid patients. METHODS: A single-blind (participant) randomised controlled feasibility trial involving 48 hypothyroid patients aged ≥80 years on established and stable levothyroxine (LT4) therapy with serum TSH levels within the standard reference range (0.4-4.0 mU/L) was conducted. Standard (0.4-4.0 mU/L) or higher (4.1-8.0 mU/L) TSH target (standard TSH [ST] or higher TSH [HT] groups) LT4 for 24 weeks was administered. The outcome measures evaluated were thyroid function tests, QoL, hypothyroid symptoms, cardiovascular risk factors and serum marker of bone resorption in participants that completed the trial (n = 21/24 ST group, n = 19/24 HT group). RESULTS: At 24 weeks, in the ST and HT groups, respectively, median (interquartile range) serum TSH was 1.25 (0.76-1.72) and 5.50 (4.05-9.12) mU/L, mean (± SD) free thyroxine (FT4) was 19.4 ± 3.5 and 15.9 ± 2.4 pmol/L, and daily LT4 dose was 82.1 ± 26.4 and 59.2 ± 23.9 µg. There was no suggestion of adverse impact of a higher serum TSH in the HT group with regard to any of the outcomes assessed. CONCLUSIONS: In hypothyroid patients aged ≥80 years on LT4 therapy for 24 weeks, there was no evidence that a higher target serum TSH was associated with an adverse impact on patient reported outcomes, cardiovascular risk factors or bone resorption marker over 24 weeks. Longer-term trials assessing morbidity and mortality outcomes and health-utility in this age group are feasible and should be performed.
INTRODUCTION: Serum thyroid-stimulating hormone (TSH) increases with age but target TSH is similar in younger and older hypothyroid patients on treatment. It is unknown if quality of life (QoL), hypothyroid symptoms and cardiovascular risk factors change in older hypothyroid patients treated to an age-appropriate reference range. OBJECTIVE: To assess if a higher target serum TSH of 4.01-8.0 mU/L is feasible in, and acceptable to, older treated hypothyroid patients. METHODS: A single-blind (participant) randomised controlled feasibility trial involving 48 hypothyroid patients aged ≥80 years on established and stable levothyroxine (LT4) therapy with serum TSH levels within the standard reference range (0.4-4.0 mU/L) was conducted. Standard (0.4-4.0 mU/L) or higher (4.1-8.0 mU/L) TSH target (standard TSH [ST] or higher TSH [HT] groups) LT4 for 24 weeks was administered. The outcome measures evaluated were thyroid function tests, QoL, hypothyroid symptoms, cardiovascular risk factors and serum marker of bone resorption in participants that completed the trial (n = 21/24 ST group, n = 19/24 HT group). RESULTS: At 24 weeks, in the ST and HT groups, respectively, median (interquartile range) serum TSH was 1.25 (0.76-1.72) and 5.50 (4.05-9.12) mU/L, mean (± SD) free thyroxine (FT4) was 19.4 ± 3.5 and 15.9 ± 2.4 pmol/L, and daily LT4 dose was 82.1 ± 26.4 and 59.2 ± 23.9 µg. There was no suggestion of adverse impact of a higher serum TSH in the HT group with regard to any of the outcomes assessed. CONCLUSIONS: In hypothyroid patients aged ≥80 years on LT4 therapy for 24 weeks, there was no evidence that a higher target serum TSH was associated with an adverse impact on patient reported outcomes, cardiovascular risk factors or bone resorption marker over 24 weeks. Longer-term trials assessing morbidity and mortality outcomes and health-utility in this age group are feasible and should be performed.
Authors: Avantika C Waring; Alice M Arnold; Anne B Newman; Petra Bùzková; Calvin Hirsch; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2012-08-09 Impact factor: 5.958
Authors: W M Tunbridge; D C Evered; R Hall; D Appleton; M Brewis; F Clark; J G Evans; E Young; T Bird; P A Smith Journal: Clin Endocrinol (Oxf) Date: 1977-12 Impact factor: 3.478
Authors: Eleanor M Simonsick; Anne B Newman; Luigi Ferrucci; Suzanne Satterfield; Tamara B Harris; Nicolas Rodondi; Douglas C Bauer Journal: Arch Intern Med Date: 2009-11-23
Authors: Nicolas Ochs; Reto Auer; Douglas C Bauer; David Nanchen; Jacobijn Gussekloo; Jacques Cornuz; Nicolas Rodondi Journal: Ann Intern Med Date: 2008-05-19 Impact factor: 25.391
Authors: Graziano Ceresini; Gian Paolo Ceda; Fulvio Lauretani; Marcello Maggio; Elisa Usberti; Michela Marina; Stefania Bandinelli; Jack M Guralnik; Giorgio Valenti; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2013-05-06 Impact factor: 7.538